COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.50M | 9.05M | 9.44M | 9.03M | 9.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.50M | 9.05M | 9.44M | 9.03M | 9.59M |
| Cost of Revenue | 4.93M | 5.04M | 5.02M | 4.76M | 4.86M |
| Gross Profit | 2.57M | 4.01M | 4.42M | 4.27M | 4.73M |
| SG&A Expenses | 10.06M | 6.33M | 7.22M | 7.63M | 6.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.94M | 16.64M | 19.78M | 20.77M | 19.52M |
| Operating Income | -10.44M | -7.58M | -10.33M | -11.74M | -9.93M |
| Income Before Tax | -10.35M | -13.82M | -17.87M | -17.07M | -15.23M |
| Income Tax Expenses | 11.00K | 1.08M | 971.00K | 496.00K | 84.00K |
| Earnings from Continuing Operations | -10.36 | -14.91 | -18.84 | -17.56 | -15.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.36M | -14.91M | -18.84M | -17.56M | -15.31M |
| EBIT | -10.44M | -7.58M | -10.33M | -11.74M | -9.93M |
| EBITDA | -11.61M | -6.63M | -9.19M | -10.51M | -8.67M |
| EPS Basic | -3.96 | -4.73 | -6.01 | -5.80 | -5.39 |
| Normalized Basic EPS | -2.42 | -1.32 | -1.90 | -1.90 | -1.79 |
| EPS Diluted | -3.96 | -4.73 | -6.01 | -5.80 | -5.39 |
| Normalized Diluted EPS | -2.42 | -1.32 | -1.90 | -1.90 | -1.79 |
| Average Basic Shares Outstanding | 15.87M | 12.64M | 12.57M | 11.61M | 10.32M |
| Average Diluted Shares Outstanding | 15.87M | 12.64M | 12.57M | 11.61M | 10.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |